Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks

BACKGROUND: Lanadelumab demonstrated efficacy in preventing hereditary angioedema (HAE) attacks in the phase 3 HELP Study. OBJECTIVE: To assess time to onset of effect and long‐term efficacy of lanadelumab, based on exploratory findings from the HELP Study. METHODS: Eligible patients with HAE type I...

Descripción completa

Detalles Bibliográficos
Autores principales: Riedl, Marc A., Maurer, Marcus, Bernstein, Jonathan A., Banerji, Aleena, Longhurst, Hilary J., Li, H. Henry, Lu, Peng, Hao, James, Juethner, Salomé, Lumry, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689768/
https://www.ncbi.nlm.nih.gov/pubmed/32452549
http://dx.doi.org/10.1111/all.14416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689768/
https://www.ncbi.nlm.nih.gov/pubmed/32452549
http://dx.doi.org/10.1111/all.14416

Ejemplares similares